Up-regulation of fas reverses cisplatin resistance of human small cell lung cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Wu, Wei ^a   Wang, Hai Dong ^b   Guo, Wei ^a   Yang, Kang ^b   Zhao, Yun Ping ^a   Jiang, Yao Guang ^a   He, Ping ^b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; FAS ANTIGEN; GLUTATHIONE TRANSFERASE P1;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL SEPARATION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; LUNG SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MULTIDRUG RESISTANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SEPARATION; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL CELL LUNG CARCINOMA;

EID: 77952062240     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-49     Document Type: Article

References (41)

1. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Eastman A, Cancer Cell 1990 2 275 280
2. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S, J Immunol 1992 148 1274 9 1371136
3. Fas and Fas ligand: a death factor and its receptor. Nagata S, Adv Immunol 1994 57 129 44 full-text 7532907
4. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H, Cancer Res 1998 58 1741 9 9563493
5. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ, Surgery 1999 125 73 84 9889801
6. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW, Nature 1996 384 638 641 10.1038/384638a0 8967952
7. Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Debatin KM, Beltinger C, Bohler T, Fellenberg J, Friesen C, Fulda S, Herr I, Los M, Scheuerpflug C, Sieverts H, Stahnke K, Biochem Soc Trans 1997 25 405 410 9191126
8. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases). Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M, Blood 1997 90 3118 3129 9376593
9. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen C, Herr I, Krammer PH, Debatin KM, Nat Med 1996 2 574 7 10.1038/nm0596-574 8616718
10. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT, J Natl Cancer Inst 1997 89 783 9 10.1093/jnci/89.11.783 9182976
11. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH, J Exp Med 1998 188 2033 45 10.1084/jem.188.11.2033 9841917
12. Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24- Induced Killing in Ovarian Carcinoma Cells. Yacoub Adly, Liu Renyan, Park Margaret A, Hamed Hossein A, Dash Rupesh, Schramm Danielle N, Sarkar Devanand, Dimitriev Igor P, Bell Jessica K, Grant Steven, Farrell Nicholas P, Curiel David T, Fisher Paul B, Dent Paul, Mol Pharmacol 2010 77 298 310 10.1124/mol.109. 061820 19910452
13. Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells? Segui Bruno, Legembre Patrick, Recent Patents on Anti-Cancer Drug Discovery 2010 5 22 28 10.2174/157489210789702190 19663773
14. Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)? Sproll Karl Christoph, Ballo Hilmar, Hoffmann Thomas K, Scheckenbach Kathrin, Koldovsky Ursula, Balz Vera, Hafner Dieter, Ramp Uwe, Bier Henning, Oral Oncology 2009 45 69 84 10.1016/j.oraloncology.2008.04.003 18620901
15. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B, Oncol Rep 1999 6 979 82 10425290
16. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR, J Clin Invest 1997 99 3 403 13 10.1172/JCI119174 9022073
17. Construction and propagation of human adenovirus vectors. Hitt M, Bett AJ, Prevec L, Graham FL, Cell Biology: Laboratory Handbook Academic Press, New York 1994 479 490
18. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Pfaffl MW, Horgan GW, Dempfle L, Nucleic Acids Res 2002 30 36 10.1093/nar/30.9.e36 11972351
19. Cell biological mechanism of multidrug resistance in tumors. Simon SM, Schindler M, Proc Natl Acad Sci USA 1994 91 3497 3504 10.1073/pnas.91.9.3497 7909602
20. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD, Proc Natl Acad Sci USA 1992 89 10772 10776 10.1073/pnas.89.22. 10772 1438274
21. Cellular predictive factors for the drug response of lung cancer. Volm M, Rittgen W, Anticancer Res 2000 20 5B 3449 58 11131647
22. Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells[J]. Toyozumi Y, Arima N, Izumaru S, Kato S, Morimatsu M, Nakashima T, Int J Oncol 2004 25 3 721 728 15289875
23. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells [J]. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J, Oncology 2000 59 4 336 343 10.1159/000012192 11096347
24. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Qin LF, Ng IO, Cancer Letters 2002 175 27 38 10.1016/S0304-3835(01)00720-0 11734333
25. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases). Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M, Blood 1997 90 3118 3129 9376593
26. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M, Pharmacotherapy 1996 16 16 39 8700790
27. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA, Mol Cell Biol 1992 12 3689 98 1380646
28. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Reed E, Cancer Treat Rev 1998 24 331 44 10.1016/S0305-7372(98)90056-1 9861196
29. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E, J Clin Invest 1994 94 703 8 10.1172/JCI117388 8040325
30. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E, Anticancer Res 2000 20 645 652 10810335
31. Applications of genomics in NSCLC. Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O, Lung Cancer 2005 50 Suppl 2 33 40 10.1016/S0169-5002(05)81571-5 16557672
32. Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L, Ai Zheng 2004 23 845 50 15248926
33. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B, Cancer Control 2003 10 297 305 12915808
34. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B, Int J Cancer 2004 110 352 361 10.1002/ijc.20134 15095299
35. Small interfering RNAinduced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ, Biochem Biophys Res Commun 2005 327 225 233 10.1016/j.bbrc.2004.12. 008 15629453
36. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Siddik ZH, Oncogene 2003 22 7265 79 10.1038/sj.onc.1206933 14576837
37. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Surowiak P, Materna V, Kaplenko I, Marek S, Dietel M, Lage H, Zabel M, Virchows Arch 2005 447 626 33 10.1007/s00428-005-1228-0 15968547
38. The relationship of the human glutathione S-transferase PI polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma. Kimura S, Imagawa Y, Satake K, Tsukuda M, Int J Mol Med 2004 14 185 9 15254763
39. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR, Cancer Res 2003 63 8097 102 14678959
40. Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Kase H, Kodama S, Nagai E, Tanaka K, Acta Cytol 1998 42 1397 402 9850649
41. Glutathioneassociated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, Waziers ID, Int J Cancer 2001 93 725 30 10.1002/ijc.1392 11477586